Investor Presentaiton

Oncology Opdivo Opdualag TIGIT Bispecific DGK Inhibitor AR LDD Subcutaneous nivolumab: Opportunity for a near-term launch potentially benefitting patients into the early 2030s Checkmate 67T1: Phase 3 study Patients with advanced or metastatic cc RCC who have received prior systemic therapy Primary Endpoint: • . Time-averaged serum concentration over 28 days (Cavgd28) Trough serum concentration at steady-state (Cmin) Key Secondary Endpoint: • ORR R 1:1 Arm A subcutaneous nivolumab + rHuPH20 Arm B intravenous nivolumab Data expected later this year & launch anticipated in 2024/2025 U.S. Regulatory path opens up indications with Q2W and Q4W dose² Indications encompass majority of Opdivo 2022 net sales in the U.S. Ill Bristol Myers Squibb™ 1. NCT04810078; 2. Supported with data from Checkmate-8KX Not for Product Promotional Use 97

View entire presentation